Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
CDNA · against 588 other Healthcare companies listed in US-listed
Ranked #215 of 589 · scores higher than 63% of peers
Bars: peers in each 10-point band of the valuation score45 peers with a valuation score of 40–49, including CDNA · Click a bar to see the companies
A mix: stronger free cash flow yield, but weaker EBITDA yield than most Healthcare peers.
| Metric | CDNA | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 577 reported | 2.4% | -4.3% | 74% | 30% | |
| EBITDA yieldHigher is better · 578 reported | 0.3% | -0.8% | 53% | 50% | |
| Free cash flow yieldHigher is better · 553 reported | 1.8% | -2.3% | 65% | 20% | |
| Book yieldHigher is better · 587 reported | 9.3% | 25.9% | 23% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 256M USD | 98 | 80 | |
| 2 | 595M USD | 96 | 97 | |
| 2 | 433M USD | 96 | 81 | |
| 2 | 289M USD | 96 | 57 | |
| 2 | 810M USD | 96 | 69 | |
| 210 | 5.7B USD | 44 | 38 | |
| 210 | 1.3B USD | 44 | 58 | |
| 210 | 66.3B USD | 44 | 30 | |
| 210 | 5.9B USD | 44 | 39 | |
| 215 | 4.6B USD | 43 | 65 | |
| 215 | 1.7B USD | 43 | 35 | |
| 215 | 16.9B USD | 43 | 37 | |
| 215 | 15.7B USD | 43 | 33 | |
| 219 | 56.7B USD | 42 | 79 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score